Prostate Cancer Reports
54

Volume 5 Number 9
September 2017



Home > Prostate Cancer Reports > Volume 5, Year 2017 > Number 9, September


CONTENTS



CLASSIFICATION
DIAGNOSIS
EPIDEMIOLOGY, RISK FACTORS AND PREVENTION
FOLLOW-UP AND QUALITY OF LIFE
INTEGRATIVE MEDICINE
OVERALL MANAGEMENT
PROGNOSIS
TREATMENT





CLASSIFICATION



Thum S, Haben B, Christ G, Sen Gupta R.
[Female prostate cancer?]
Pathologe. 2017 Jul 20. doi: 10.1007/s00292-017-0322-9. [Epub ahead of print] German.
Source | Abstract | Full text | Similar articles





DIAGNOSIS



Gasparrini S, Cimadamore A, Scarpelli M, Massari F, Doria A, Mazzucchelli R, Cheng L, Lopez-Beltran A, Montironi R.
Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians.
Asian J Androl. 2017 Aug 4. doi: 10.4103/aja.aja_24_17. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Holtz JN, Silverman RK, Tay KJ, Browning JT, Huang J, Polascik TJ, Gupta RT.
New prostate cancer prognostic grade group (PGG): Can multiparametric MRI (mpMRI) accurately separate patients with low-, intermediate-, and high-grade cancer?
Abdom Radiol (NY). 2017 Jul 18. doi: 10.1007/s00261-017-1255-8. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Maurer T, Eiber M, Fanti S, Budäus L, Panebianco V.
Imaging for Prostate Cancer Recurrence.
Eur Urol Focus. 2016 Jun;2(2):139-150. doi: 10.1016/j.euf.2016.02.006. Epub 2016 Feb 22.
Source | Abstract | Full text | Similar articles




Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, Pienta KJ, Allaf ME, Haberkorn U, Pomper MG, Gorin MA, Rowe SP.
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.
Eur J Nucl Med Mol Imaging. 2017 Aug 1. doi: 10.1007/s00259-017-3780-7. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
Eur Urol Focus. 2016 Nov 15. pii: S2405-4569(16)30160-2. doi: 10.1016/j.euf.2016.11.002. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





EPIDEMIOLOGY, RISK FACTORS AND PREVENTION



Helgstrand JT, Røder MA, Klemann N, Toft BG, Brasso K, Vainer B, Iversen P.
Diagnostic characteristics of lethal prostate cancer.
Eur J Cancer. 2017 Aug 2;84:18-26. doi: 10.1016/j.ejca.2017.07.007. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





FOLLOW-UP AND QUALITY OF LIFE



Ervandian M, Høyer M, Petersen SE, Sengeløv L, Hansen S, Kempel MM, Meidahl Petersen P, Borre M.
Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer
Scand J Urol. 2017 Jul 27:1-7. doi: 10.1080/21681805.2017.1354314. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Lardas M, Liew M, van den Bergh RC, De Santis M, Bellmunt J, Van den Broeck T, Cornford P, Cumberbatch MG, Fossati N, Gross T, Henry AM, Bolla M, Briers E, Joniau S, Lam TB, Mason MD, Mottet N, van der Poel HG, Rouvière O, Schoots IG, Wiegel T, Willemse PM, Yuan CY, Bourke L.
Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review.
Eur Urol. 2017 Jul 27. pii: S0302-2838(17)30535-3. doi: 10.1016/j.eururo.2017.06.035. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Penson DF.
Quality of Life Outcomes Following Treatment for Localized Prostate Cancer: What's New and What's Not.
Eur Urol. 2017 Jul 20. pii: S0302-2838(17)30588-2. doi: 10.1016/j.eururo.2017.07.010. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





INTEGRATIVE MEDICINE



Deng Y, Li Y, Yang F, Zeng A, Yang S, Luo Y, Zhang Y, Xie Y, Ye T, Xia Y, Yin W.
The extract from Punica granatum (pomegranate) peel induces apoptosis and impairs metastasis in prostate cancer cells.
Biomed Pharmacother. 2017 Sep;93:976-984. doi: 10.1016/j.biopha.2017.07.008. Epub 2017 Jul 14.
Source | Abstract | Full text | Similar articles




Hamilton RJ.
Making Sense of the Statin-Prostate Cancer Relationship: Is It Time for a Randomized Controlled Trial?
Eur Urol Focus. 2016 Jun 23. pii: S2405-4569(16)30068-2. doi: 10.1016/j.euf.2016.06.008. [Epub ahead of print] Online 2016 Oct 17.
Source | Abstract | Full text | Similar articles




Larsen SB, Dehlendorff C, Skriver C, Dalton SO, Jespersen CG, Borre M, Brasso K, Nørgaard M, Johansen C, Sørensen HT, Hallas J, Friis S.
Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer.
J Clin Oncol. 2017 Aug 14:JCO2016718981. doi: 10.1200/JCO.2016.71.8981. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Murtola TJ, Peltomaa AI, Talala K, Määttänen L, Taari K, Tammela TLJ, Auvinen A.
Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.
Eur Urol Focus. 2016 Jun 2. pii: S2405-4569(16)30052-9. doi: 10.1016/j.euf.2016.05.004. [Epub ahead of print] Online 2016 Oct 17.
Source | Abstract | Full text | Similar articles




Tenta R, Fragopoulou E, Tsoukala M, Xanthopoulou M, Skyrianou M, Pratsinis H, Kletsas D.
Antiproliferative Effects of Red and White Wine Extracts in PC-3 Prostate Cancer Cells.
Nutr Cancer. 2017 Jul 25:1-10. doi: 10.1080/01635581.2017.1340489. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





OVERALL MANAGEMENT



Dell'Oglio P, Sanchez-Salas R.
Most of patients with localized prostate cancer will be treated in the future? | Opinion: Yes.
Int Braz J Urol. 2017 Jul-Aug;43(4):579-583. doi: 10.1590/S1677-5538.IBJU.2017.04.02.
Source | Abstract | Full text | Similar articles




Schulman AA, Polascik TJ.
Most of patients with localized prostate cancer will be treated in the future? | Opinion: No.
Int Braz J Urol. 2017 Jul-Aug;43(4):584-587. doi: 10.1590/S1677-5538.IBJU.2017.04.03.
Source | Abstract | Full text | Similar articles





PROGNOSIS



Emmett L, Van Leeuwen P, Nandurkar R, Scheltema MJ, Cusick T, Hruby G, Kneebone A, Eade T, Fogarty G, Jagavkar R, Nguyen Q, Ho B, Joshua AM, Stricker P.
Treatment outcomes from 68GaPSMA PET CT informed salvage radiation treatment in men with rising PSA following radical prostatectomy: Prognostic value of a negative PSMA PET.
J Nucl Med. 2017 Jul 26. pii: jnumed.117.196683. doi: 10.2967/jnumed.117.196683. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Fossati N, Karnes RJ, Colicchia M, Boorjian SA, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Dell'Oglio P, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Wiegel T, Montorsi F, Briganti A.
Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy.
Eur Urol. 2017 Aug 2. pii: S0302-2838(17)30655-3. doi: 10.1016/j.eururo.2017.07.026. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Henderickx MMEL, Brits T, Muilwijk T, Adams T, Vandeursen H.
Localized prostate cancer and robot-assisted laparoscopic radical prostatectomy: a retrospective, comparative study between pre- and post-operative Gleason scores.
Acta Chir Belg. 2017 Jul 18:1-6. doi: 10.1080/00015458.2017.1353234. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Kurbegovic S, Berg KD, Thomsen FB, Gruschy L, Iversen P, Brasso K, Røder MA.
The risk of biochemical recurrence for intermediate-risk prostate cancer after radical prostatectomy.
Scand J Urol. 2017 Aug 1:1-7. doi: 10.1080/21681805.2017.1356369. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Nassiri N, Margolis DJ, Natarajan S, Sharma DS, Huang J, Dorey FJ, Marks LS.
Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer.
J Urol. 2017 Mar;197(3 Pt 1):632-639. doi: 10.1016/j.juro.2016.09.070. Epub 2016 Sep 14.
Source | Abstract | Full text | Similar articles




Pessoa RR, Viana PC, Mattedi RL, Guglielmetti GB, Cordeiro MD, Coelho RF, Nahas WC, Srougi M.
Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
BJU Int. 2017 Apr;119(4):535-542. doi: 10.1111/bju.13624. Epub 2016 Sep 3.
Source | Abstract | Full text | Similar articles




Patel HD, Tosoian JJ, Carter HB, Epstein JI.
Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group.
JAMA Oncol. 2017 Jul 13. doi: 10.1001/jamaoncol.2017.1879. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Rajan P, Hagman A, Sooriakumaran P, Nyberg T, Wallerstedt A, Adding C, Akre O, Carlsson S, Hosseini A, Olsson M, Egevad L, Wiklund F, Steineck G, Wiklund NP.
Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up.
Eur Urol Focus. 2016 Nov 2. pii: S2405-4569(16)30154-7. doi: 10.1016/j.euf.2016.10.007. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Røder MA, Berg KD, Loft MD, Thomsen FB, Ferrari M, Kurbegovic S, Rytgaard HC, Gruschy L, Brasso K, Gerds TA, Kjær A, Brooks JD, Iversen P.
The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy.
Eur Urol Focus. 2016 Dec 9. pii: S2405-4569(16)30172-9. doi: 10.1016/j.euf.2016.11.014. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Skove SL, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moreira DM, Freedland SJ.
Timing of PSA Nadir after Radical Prostatectomy and Risk of Biochemical Recurrence.
Urology. 2017 Jul 19. pii: S0090-4295(17)30742-2. doi: 10.1016/j.urology.2017.07.009. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





TREATMENT



Das M.
Surgery no better than observation for localised prostate cancer.
Lancet Oncol. 2017 Jul 20. pii: S1470-2045(17)30565-X. doi: 10.1016/S1470-2045(17)30565-X. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Klotz L.
Active Surveillance for Intermediate Risk Prostate Cancer.
Curr Urol Rep. 2017 Aug 11;18(10):80. doi: 10.1007/s11934-017-0726-3.
Source | Abstract | Full text | Similar articles




Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY.
A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.
Eur Urol. 2017 Jul 14. pii: S0302-2838(17)30527-4. doi: 10.1016/j.eururo.2017.06.027. [Epub ahead of print]
Source | Abstract | Full text | Similar articles